Clinical genome interpretation technology producer Omicia has secured capital from investors including Roche, Ping An and UPMC to accelerate product development.
US-based healthcare software provider Omicia closed a $23m series B round yesterday featuring Roche Venture Fund and Ping An Ventures, the respective investment subsidaries of pharmaceutical company Roche and insurance provider Ping An.
UPMC Enterprises, the investment and commercialisation arm of Pittsburgh University hospital UPMC, LDV Partners, Artis Ventures, Acadia Woods Partners and Buchanan Investments and one unnamed genomics investor also supplied funds.
Omicia provides next-generation sequencing platform, named Opal, to analyse, interpret and report on genomic data, such as…
